Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Allison Dorval Sells 11,610 Shares

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Allison Dorval sold 11,610 shares of the firm's stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $3.40, for a total transaction of $39,474.00. Following the completion of the transaction, the director now directly owns 75,390 shares in the company, valued at $256,326. This represents a 13.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Puma Biotechnology Stock Performance

Shares of PBYI traded down $0.02 during mid-day trading on Tuesday, reaching $3.43. 210,811 shares of the company's stock traded hands, compared to its average volume of 443,805. The business's 50-day moving average price is $3.20 and its 200-day moving average price is $3.12. The stock has a market capitalization of $170.23 million, a P/E ratio of 4.45 and a beta of 1.29. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.43 and a current ratio of 1.53. Puma Biotechnology, Inc. has a 12 month low of $2.23 and a 12 month high of $4.13.

Institutional Investors Weigh In On Puma Biotechnology

A number of hedge funds have recently made changes to their positions in PBYI. Acorn Capital Advisors LLC bought a new stake in shares of Puma Biotechnology during the fourth quarter valued at approximately $7,475,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Puma Biotechnology by 70.6% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 831,689 shares of the biopharmaceutical company's stock worth $2,462,000 after purchasing an additional 344,321 shares in the last quarter. Kennedy Capital Management LLC raised its holdings in Puma Biotechnology by 36.5% during the fourth quarter. Kennedy Capital Management LLC now owns 809,375 shares of the biopharmaceutical company's stock worth $2,469,000 after purchasing an additional 216,329 shares in the last quarter. American Century Companies Inc. raised its holdings in Puma Biotechnology by 21.2% during the first quarter. American Century Companies Inc. now owns 1,149,660 shares of the biopharmaceutical company's stock worth $3,403,000 after purchasing an additional 201,284 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Puma Biotechnology by 24.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 863,760 shares of the biopharmaceutical company's stock worth $2,635,000 after purchasing an additional 170,968 shares in the last quarter. Institutional investors own 61.29% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $7.00 target price on shares of Puma Biotechnology in a report on Friday, February 28th. Wall Street Zen raised Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 22nd.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.